Earle Burgess: Another interesting new drug in development for metastatic castrate resistant prostate cancer

Earle Burgess, Genitourinary Medical Oncologist at Atrium Health, Levine Cancer Institute, shared on LinkedIn:

”ARV-766: another interesting new drug in development for metastatic castrate resistant prostate cancer (mCRPC) with promising early phase data presented at ASCO24.

ARV-766 is an AR ‘PROTAC,’ a molecule that enhances degradation of the androgen receptor (AR) inside of prostate cancer cells.

20-25% of patients with mCRPC have tumor mutations in the AR ligand binding domain (LBD).

In a small cohort of heavily pretreated mCRPC patients whose tumors had mutations in the AR LBD, ARV-766 led to a 50% decrease in PSA levels in 43% of patients.

Impressive preliminary data for this patient population.”

Source: Earle Burgess/LinkedIn